Bukwang Pharm

Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. Its offerings include oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company provides ethical drugs for conditions such as diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, liver cirrhosis, and iron-deficiency anemia; over-the-counter drugs including fever and pain relief, gastrointestinal, and cold medications, laxatives, collagen and multivitamin supplements, mouthwash, topical gels, oral health supplements, and omega-3 supplements; and personal products such as toothpastes, toothbrushes, and other oral care products, as well as nutraceuticals, health functional foods, and quasi drugs. It also offers products for therapeutic areas including endocrinology, gastroenterology, cardiology, oncology, central nervous system, iron supplements, neuropsychiatry, respiratory/allergy, dermatology, and urology. Its development pipeline includes Lurasidone for schizophrenia and bipolar depression, JM-010 for dyskinesia in Parkinson's disease, SOL-804 for metastatic castration-resistant prostate cancer, an AhR inhibitor for solid tumors, a PKR inhibitor for neurodegenerative disorders, and a PD program for Parkinson's disease. Founded in 1960, the company is headquartered in Seoul, South Korea.